Analysts Set Aptose Biosciences Inc. (NASDAQ:APTO) Price Target at $9.40

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been given a consensus recommendation of “Buy” by the six research firms that are covering the company, reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.40.

Several research analysts have recently issued reports on the company. HC Wainwright increased their target price on Aptose Biosciences from $9.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 12th. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Tuesday, November 16th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Aptose Biosciences in a research note on Wednesday, November 17th.

In other Aptose Biosciences news, VP Rafael Bejar bought 10,000 shares of the business’s stock in a transaction on Friday, November 19th. The shares were acquired at an average cost of $2.56 per share, for a total transaction of $25,600.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 8.41% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Newman Dignan & Sheerar Inc. purchased a new position in shares of Aptose Biosciences in the 3rd quarter worth $28,000. Squarepoint Ops LLC purchased a new position in shares of Aptose Biosciences in the 3rd quarter worth $34,000. UBS Group AG boosted its stake in shares of Aptose Biosciences by 102.1% in the 3rd quarter. UBS Group AG now owns 18,478 shares of the biotechnology company’s stock worth $40,000 after buying an additional 9,333 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in Aptose Biosciences by 150.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 20,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 12,000 shares during the period. Finally, WealthShield Partners LLC bought a new position in Aptose Biosciences in the 2nd quarter worth $135,000. Institutional investors and hedge funds own 63.64% of the company’s stock.

APTO traded down $0.05 during midday trading on Thursday, reaching $2.40. 794,628 shares of the company’s stock traded hands, compared to its average volume of 1,948,004. The firm has a fifty day moving average of $2.38 and a two-hundred day moving average of $3.15. The stock has a market capitalization of $213.48 million, a price-to-earnings ratio of -3.81 and a beta of 1.62. Aptose Biosciences has a 52 week low of $2.02 and a 52 week high of $7.27.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Thursday, November 11th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same period in the prior year, the business posted ($0.15) earnings per share. As a group, equities analysts predict that Aptose Biosciences will post -0.66 earnings per share for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also: What is the Producer Price Index (PPI)?

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.